Peroxisome proliferator-activated receptor and AMP-activated protein kinase agonists protect against lethal influenza virus challenge in mice

Influenza and other Respiratory Viruses

Volumn 4, Issue 5, 2010, Pages 307-311

  Moseley, Carson E ^a   Webster, Robert G ^a   Aldridge, Jerry R ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Inflammation; Influenza; PPAR

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; PIOGLITAZONE; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT RESPONSE; WEIGHT REDUCTION;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; BODY WEIGHT; FEMALE; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H1N1 SUBTYPE; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; SURVIVAL ANALYSIS;

EID: 77955796417     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/j.1750-2659.2010.00155.x     Document Type: Article

References (22)

1. Ahmed R, Oldstone MB, Palese P. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol 2007, 8:1188-1193.
2. Dawood FS, Jain S, Finelli L. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009, 360:2605-2615.
3. Basler CF. Influenza viruses: basic biology and potential drug targets. Infect Disord Drug Targets 2007, 7:282-293.
4. Chan MC, Cheung CY, Chui WH. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res 2005, 6:135.
5. Cheung CY, Poon LL, Lau AS. Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? Lancet 2002, 360:1831-1837.
6. Kobasa D, Jones SM, Shinya K. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 2007, 445:319-323.
7. Loo YM, Gale M. Influenza: fatal immunity and the 1918 virus. Nature 2007, 445:267-268.
8. Fedson DS. Confronting an influenza pandemic with inexpensive generic agents: can it be done? Lancet Infect Dis 2008, 8:571-576.
9. Fedson DS. Meeting the challenge of influenza pandemic preparedness in developing countries. Emerg Infect Dis 2009, 15:365-371.
10. Fedson DS. Confronting the next influenza pandemic with anti-inflammatory and immunomodulatory agents: why they are needed and how they might work. Influenza Other Respi Viruses 2009, 3:129-142.
11. Fedson DS, Dunnill P. Commentary: from scarcity to abundance: pandemic vaccines and other agents for " have not" countries. J Public Health Policy 2007, 28:322-340.
12. Aldridge JR, Moseley CE, Boltz DA. TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection. Proc Natl Acad Sci U S A 2009, 106:5306-5311.
13. Herold S, von Wulffen W, Steinmueller M. Alveolar epithelial cells direct monocyte transepithelial migration upon influenza virus infection: impact of chemokines and adhesion molecules. J Immunol 2006, 177:1817-1824.
14. Lin KL, Suzuki Y, Nakano H, Ramsburg E, Gunn MD. CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol 2008, 180:2562-2572.
15. Di Gregorio GB, Yao-Borengasser A, Rasouli N. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes 2005, 54:2305-2313.
16. Haraguchi G, Kosuge H, Maejima Y. Pioglitazone reduces systematic inflammation and improves mortality in apolipoprotein E knockout mice with sepsis. Intensive Care Med 2008, 34:1304-1312.
17. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008, 454:470-477.
18. Keller H, Dreyer C, Medin J. Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. Proc Natl Acad Sci USA 1993, 90:2160-2164.
19. Budd A, Alleva L, Alsharifi M. Increased survival after gemfibrozil treatment of severe mouse influenza. Antimicrob Agents Chemother 2007, 51:2965-2968.
20. Pitocco D, Giubilato S, Zaccardi F. Pioglitazone reduces monocyte activation in type 2 diabetes. Acta Diabetol 2009, 46:75-77.
21. Dharan NJ, Gubareva LV, Meyer JJ. Infections with oseltamivir-resistant influenza A (H1N1) virus in the United States. JAMA 2009, 301:1034-1041.
22. de Jong MD, Simmons CP, Thanh TT. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 2006, 12:1203-1207.